The urgent need to recover MHC class I in cancers for effective immunotherapy
Open accessAbstract
Immune escape strategies aimed to avoid T-cell recognition, including the loss of tumor MHC class I expression, are commonly found in malignant cells. Tumor immune escape has proven to have a negative effect on the clinical outcome of cancer immunotherapy, including treatment with antibodies blocking immune checkpoint molecules. Hence, there is an urgent need to develop novel approaches to overcome tumor immune evasion. MHC class I antigen presentation is often affected in human cancers and the capacity to induce upregulation of MHC class I cell surface expression is a critical step in the induction of tumor rejection. This review focuses on characterization of rejection, escape, and dormant profiles of tumors and its microenvironment with a special emphasis on the tumor MHC class I expression. We also discuss possible approaches to recover MHC class I expression on tumor cells harboring reversible/'soft' or irreversible/'hard' genetic lesions. Such MHC class I recovery approaches might well synergize with complementary forms of immunotherapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ERK inhibitors drive increased autophagic flux in PDAC cells to facilitate survival.
“Inhibition of the mutant KRAS-MEK-MAPK signaling cascade using ERK inhibitors drives increased autophagic flux in PDAC cells to facilitate survival224,225”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [225]
Metabolic inhibition approaches combined with RAS pathway inhibitors have shown strong preclinical data and are currently in clinical trials.
“metabolic inhibition approaches combined with RAS pathway inhibitors have shown strong pre-clinical data and are currently in clinical trials197,224,225”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [225]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 1× · see citing works
“One of the major problems facing any type of cancer treatment is the extensive heterogeneity of primary tumors, which arises as a result of genetic and epigenetic alterations at a clonal level (17,18).”
BackgroundDetection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067 · see citing works
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862 · see citing works
Rosenberg, S. A., Lotze, M. T., Muul, L. M., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704093161501 · Cited by 2,762 · see citing works
Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder Tumors
Morales, Á., Eidinger, D., & Bruce, A. W. (1976) · The Journal of Urology · doi:10.1016/s0022-5347(17)58737-6 · Cited by 1,796 · see citing works
Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors
Morales, Á., Eidinger, D., & Bruce, A. W. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.10.101 · Cited by 1,537 · see citing works
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,438 · see citing works
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,173 · see citing works
Cancer heterogeneity: implications for targeted therapeutics
Fisher, R. A., Pusztai, L., & Swanton, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.581 · Cited by 980 · see citing works
Intracavitary bacillus Calmette-Grerin in the treatement of superficial bladder tumors
Morales, A. (1976) · The Journal of Urology · Cited by 978 · see citing works
In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer
Pagès, F., Kirilovsky, A., Mlecnik, B., Asslaber, M., Tosolini, M., Bindea, G., Lagorce, C., Wind, P., Marliot, F., Bruneval, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6147 · Cited by 953 · see citing works
Implications for immunosurveillance of altered HLA class I phenotypes in human tumours
Garrido, F., Ruiz‐Cabello, F., Cabrera, T., Pérez‐Villar, J. J., López‐Botet, M., Duggan-Keen, M. F., & Stern, P. L. (1997) · Immunology Today · doi:10.1016/s0167-5699(96)10075-x · Cited by 768 · see citing works
Self-citationKim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676 · see citing works
Rosenberg, S. A., Sherry, R. M., Morton, K. E., Sharfman, W., Yang, J. C., Topalian, S. L., Royal, R. E., Kammula, U. S., Restifo, N. P., Hughes, M. S., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.6169 · Cited by 460 · see citing works
Natural history of HLA expression during tumour development
Garrido, F., Cabrera, T., Concha, Á., Glew, S., Ruiz‐Cabello, F., & Stern, P. L. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90264-l · Cited by 448 · see citing works
Self-citationSustained effector function of IL-12/15/18–preactivated NK cells against established tumors
Ni, J., Miller, M., Stojanovic, A., Garbi, N., & Cerwenka, A. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20120944 · Cited by 416 · see citing works
Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 + T cell response
Kvistborg, P., Philips, D., Kelderman, S., Hageman, L., Ottensmeier, C. H. H., Joseph‐Pietras, D., Welters, M. J. P., van der Burg, S., Kapiteijn, E., Michielin, O. A., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008918 · Cited by 378 · see citing works
CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
Robert, L., Tsoi, J., Wang, X., Emerson, R., Homet, B., Chodon, T., Mok, S., Huang, R., Cochran, A. J., Comı́n-Anduix, B., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2648 · Cited by 373 · see citing works
Genome Sequencing and Analysis of the Tasmanian Devil and Its Transmissible Cancer
Murchison, E. P., Schulz-Trieglaff, O. B., Ning, Z., Alexandrov, L. B., Bauer, M. J., Fu, B., Hims, M. M., Ding, Z., Ivakhno, S., Stewart, C. M., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.065 · Cited by 320 · see citing works
MHC antigens and tumor escape from immune surveillance
Garrido, F., & Algarra, I. (2001) · Advances in cancer research · doi:10.1016/s0065-230x(01)83005-0 · Cited by 305 · see citing works
Self-citationImmune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
Rusakiewicz, S., Semeraro, M., Sarabi, M., Desbois, M., Locher, C., Mendez, R., Vimond, N., Concha, Á., Garrido, F., Isambert, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0371 · Cited by 304 · see citing works
Self-citationKoopman, L. A., Corver, W. E., van der Slik, A. R., Giphart, M. J., & Fleuren, G. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.6.961 · Cited by 279 · see citing works
Garrido, F., Cabrera, T., & Aptsiauri, N. (2010) · International Journal of Cancer · doi:10.1002/ijc.25270 · Cited by 276 · see citing works
Self-citationHLA class I antigen abnormalities and immune escape by malignant cells
Seliger, B., Cabrera, T., Garrido, F., & Ferrone, S. (2002) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0404 · Cited by 272 · see citing works
Self-citationSiddle, H. V. T., Kreiss, A., Tovar, C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219920110 · Cited by 248 · see citing works
Control of T-Cell–Mediated Immune Response by HLA Class I in Human Pancreatic Carcinoma
Ryschich, E., Noetzel, T., Hinz, U., Autschbach, F., Ferguson, J. G., Şimon, I., Weitz, J., Fröhlich, B., Klar, E., Büchler, M. W., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.498.11.2 · Cited by 212 · see citing works
Cytokine therapy reverses NK cell anergy in MHC-deficient tumors
Ardolino, M., Azimi, C. S., Iannello, A., Trevino, T. N., Horan, L. H., Zhang, L., Deng, W., Ring, A. M., Fischer, S., García, K. C., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74337 · Cited by 192 · see citing works
Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases
Corbière, V., Chapiro, J., Stroobant, V., Ma, W., Lurquin, C., Lethé, B., van Baren, N., den Eynde, B. J. V., Boon, T., & Coulie, P. G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2693 · Cited by 176 · see citing works
Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants
van Hall, T., Wolpert, E. Z., van Veelen, P. A., Laban, S., van der Veer, M., Roseboom, M., Bres-Vloemans, S. A., Grufman, P., de Ru, A., Meiring, H. D., et al. (2006) · Nature Medicine · doi:10.1038/nm1381 · Cited by 160 · see citing works
The immunologic constant of rejection
Wang, E., Worschech, A., & Marincola, F. M. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.03.002 · Cited by 158 · see citing works
Immune escape of cancer cells with beta2‐microglobulin loss over the course of metastatic melanoma
Campo, A. B., Kyte, J. A., Carretero, J., Zinchencko, S., Méndez, R., González‐Aseguinolaza, G., Ruiz‐Cabello, F., Aamdal, S., Gaudernack, G., Garrido, F., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28338 · Cited by 147 · see citing works
Self-citationBladder Cancer Immunotherapy: BCG and Beyond
Askeland, E. J., Newton, M. R., O’Donnell, M. A., & Luo, Y. (2012) · Advances in Urology · doi:10.1155/2012/181987 · Cited by 147 · see citing works
Immune evasion of microsatellite unstable colorectal cancers
Kloor, M., Michel, S., & Doeberitz, M. V. K. (2010) · International Journal of Cancer · doi:10.1002/ijc.25283 · Cited by 138 · see citing works
Fiegler, N., Textor, S., Arnold, A., Rölle, A., Oehme, I., Breuhahn, K., Moldenhauer, G., Witzens‐Harig, M., & Cerwenka, A. (2013) · Blood · doi:10.1182/blood-2013-02-482513 · Cited by 135 · see citing works
Carretero, R., Romero, J. M., Ruiz‐Cabello, F., Maleno, I., Rodriguez, F., Camacho, F. M., Real, L. M., Garrido, F., & Cabrera, T. (2008) · Immunogenetics · doi:10.1007/s00251-008-0303-5 · Cited by 128 · see citing works
Self-citationTumour immunology: MHC antigens and malignancy
FESTENSTEIN, H., & Garrido, F. (1986) · Nature · doi:10.1038/322502a0 · Cited by 121 · see citing works
Self-citationGuo, W., Lonardo, F., Ueda, T., Kim, T. K., Huvos, A. G., Healey, J. H., & Ladanyi, M. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990118)80:2 · Cited by 120 · see citing works
Analysis of HLA expression in human tumor tissues
Cabrera, T., López‐Nevot, M. Á., Gaforio, J. J., Ruiz‐Cabello, F., & Garrido, F. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-002-0332-0 · Cited by 119 · see citing works
Self-citationYang, H., Lan, P., Hou, Z., Guan, Y., Zhang, J., Xu, W., Tian, Z., & Zhang, C. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.547 · Cited by 115 · see citing works
Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes
Bernal, M., Ruiz‐Cabello, F., Concha, Á., Paschen, A., & Garrido, F. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1321-6 · Cited by 114 · see citing works
Self-citationZhu, S., Denman, C. J., Cobanoglu, Z. S., Kiany, S., Lau, C. C., Gottschalk, S. M., Hughes, D. P. M., Kleinerman, E. S., & Lee, D. A. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1231-0 · Cited by 110 · see citing works
Maleno, I., Cabrera, C., Cabrera, T., Paco, L., López‐Nevot, M. Á., Collado, A., Ferr�n, A., & Garrido, F. (2004) · Immunogenetics · doi:10.1007/s00251-004-0692-z · Cited by 93 · see citing works
Self-citationCarretero, R., Wang, E., Rodríguez, A. I. E., Reinboth, J., Ascierto, M. L., Engle, A. M., Liu, H., Camacho, F. M., Marincola, F. M., Garrido, F., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26471 · Cited by 88 · see citing works
Self-citationGarcia-Lora, A. M., Martinez, M., Algarra, I., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.11241 · Cited by 88 · see citing works
Self-citationMetastases in Immune-Mediated Dormancy: A New Opportunity for Targeting Cancer
Romero, I., Garrido, F., & Garcia-Lora, A. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2406 · Cited by 86 · see citing works
Self-citationStrategies to counteract MHC-I defects in tumors
Lampen, M. H., & van Hall, T. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.12.005 · Cited by 82 · see citing works
Maleno, I., Aptsiauri, N., Cabrera, T., Gallego, Á. O., Paschen, A., López‐Nevot, M. Á., & Garrido, F. (2010) · Immunogenetics · doi:10.1007/s00251-010-0494-4 · Cited by 81 · see citing works
Self-citationTAP-independent self-peptides enhance T cell recognition of immune-escaped tumors
Doorduijn, E. M., Sluijter, M., Querido, B. J., Oliveira, C. C., Achour, A., OSSENDORP, F. A., van der Burg, S. H., & van Hall, T. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83671 · Cited by 81 · see citing works
Self-citationAlternative Antigen Processing for MHC Class I: Multiple Roads Lead to Rome
Oliveira, C. C., & van Hall, T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00298 · Cited by 72 · see citing works
T Lymphocytes Restrain Spontaneous Metastases in Permanent Dormancy
Romero, I., Garrido, C., Algarra, I., Collado, A., Garrido, F., & Garcia-Lora, A. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2084 · Cited by 72 · see citing works
Self-citationNovel insights into the molecular mechanisms of HLA class I abnormalities
Seliger, B. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1153-9 · Cited by 71 · see citing works
Targeting HLA class I expression to increase tumor immunogenicity
Campo, A. B., Carretero, J., Aptsiauri, N., & Garrido, F. (2012) · Tissue Antigens · doi:10.1111/j.1399-0039.2011.01831.x · Cited by 53 · see citing works
Self-citationGeneration of MHC class I diversity in primary tumors and selection of the malignant phenotype
Garrido, F., Romero, I., Aptsiauri, N., & Garcia-Lora, A. M. (2014) · International Journal of Cancer · doi:10.1002/ijc.29375 · Cited by 51 · see citing works
Self-citationEpigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
Park, J., Thomas, S., & Munster, P. (2015) · Epigenomics · doi:10.2217/epi.15.16 · Cited by 49 · see citing works
Šímová, J., Polláková, V., Indrová, M., Mikyšková, R., Bieblová, J., Štěpánek, I., Bubenik, J., & Reiniš, M. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.428 · Cited by 47 · see citing works
The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells
Romero, I., Martinez, M., Garrido, C., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4029 · Cited by 43 · see citing works
Garrido, F. (1996) · Tissue Antigens · doi:10.1111/j.1399-0039.1996.tb02570.x · Cited by 40 · see citing works
Self-citationCampo, A. B., Aptsiauri, N., Méndez, R., Zinchenko, S. P., Vales, Á., Paschen, A., Ward, S., Ruiz‐Cabello, F., González‐Aseguinolaza, G., & Garrido, F. (2009) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2009.02276.x · Cited by 40 · see citing works
Self-citationVlková, V., Štěpánek, I., Hrušková, V., Šenigl, F., Mayerová, V., Šrámek, M., Šímová, J., Bieblová, J., Indrová, M., Hejhal, T., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2222 · Cited by 39 · see citing works
New Role of Signal Peptide Peptidase To Liberate C-Terminal Peptides for MHC Class I Presentation
Oliveira, C. C., Querido, B. J., Sluijter, M., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301496 · Cited by 39 · see citing works
Garrido, G., Rabasa, A., Garrido, C., López, A., Chao, L., Garcia-Lora, A. M., Garrido, F., Fernandez, L. E., & Sánchez, B. (2013) · Oncogene · doi:10.1038/onc.2013.288 · Cited by 36 · see citing works
Self-citationA novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens
Seidel, U. J. E., Oliveira, C. C., Lampen, M. H., & van Hall, T. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1160-x · Cited by 35 · see citing works
Campo, A. B., Carretero, J., Muñoz, J. A., Zinchenko, S. P., Ruiz‐Cabello, F., González‐Aseguinolaza, G., Garrido, F., & Aptsiauri, N. (2014) · Cancer Gene Therapy · doi:10.1038/cgt.2014.32 · Cited by 35 · see citing works
Self-citationImmunotherapy eradicates metastases with reversible defects in MHC class I expression
Garrido, C., Romero, I., Berruguilla, E., Cancela, B., Algarra, I., Collado, A., Garcia-Lora, A. M., & Garrido, F. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1027-1 · Cited by 32 · see citing works
Self-citationImportance of TAP-independent processing pathways
Oliveira, C. C., & van Hall, T. (2012) · Molecular Immunology · doi:10.1016/j.molimm.2012.10.005 · Cited by 32 · see citing works
Immunology of a Transmissible Cancer Spreading among Tasmanian Devils
Woods, G. M., Howson, L. J., Brown, G. K., Tovar, C., Kreiss, A., Corcoran, L. M., & Lyons, A. B. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500131 · Cited by 29 · see citing works
Buferne, M., Chasson, L., Grange, M., Mas, A., Arnoux, F., Bertuzzi, M., Naquet, P., Leserman, L., Schmitt‐Verhulst, A., & Auphan‐Anezin, N. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.974959 · Cited by 25 · see citing works
Cózar, J. M., Aptsiauri, N., Tallada, M., Garrido, F., & Ruiz‐Cabello, F. (2008) · Journal of Medical Case Reports · doi:10.1186/1752-1947-2-111 · Cited by 19 · see citing works
Self-citationTumor Immunology and Immunotherapy
Hofmann, S., Khan, G., Boncheva, V. B., et al. (2014) · Oxford University Press eBooks · doi:10.1093/med/9780199676866.001.0001 · Cited by 18 · see citing works
Adaptive T-cell immunity and tumor antigen recognition
Romero, P. J., & Coulie, P. G. (2014) · Oxford University Press eBooks · doi:10.1093/med/9780199676866.003.0001 · Cited by 8 · see citing works
‘Hard’ and ‘soft’ loss of MHC class I expression in cancer cells
Aptsiauri, N., Garcia-Lora, A. M., & Garrido, F. (2014) · Oxford University Press eBooks · doi:10.1093/med/9780199676866.003.0005 · Cited by 7 · see citing works
Self-citationB7-H Abnormalities in Melanoma and Clinical Relevance
Seliger, B. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-727-3_19 · Cited by 4 · see citing works
Cowan (2001) · doi:10.1002/1097-0215(20010101)91:1
Flagged first, then by citations
Research works printed but not linked: 1
- [35]Garrido F. Klein E. MHC antigen expression. I. Human tumors Klein E. Garrido F. Seminars in Cancer Biology vol 2-1 1991 W.B. Saunders Scientific Publications 1 2
Cited by
Sorted by citations
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154 · see citing works
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207 · see citing works
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368 · see citing works
Pancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321 · see citing works
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077 · see citing works
Integrating oncolytic viruses in combination cancer immunotherapy
Bommareddy, P. K., Shettigar, M., & Kaufman, H. L. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0014-6 · Cited by 704 · see citing works
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202170126 · Cited by 531 · see citing works
Ennishi, D., Takata, K., Béguelin, W., Duns, G., Mottok, A., Farinha, P., Bashashati, A., Saberi, S., Boyle, M., Meissner, B., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1090 · Cited by 318 · see citing works
MIF-Dependent Control of Tumor Immunity
Noe, J. T., & Mitchell, R. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.609948 · Cited by 198 · see citing works
<p>Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor</p>
Bai, X., Yi, M., Jiao, Y., Chu, Q., & Wu, K. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s224013 · Cited by 153 · see citing works
HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy
Anderson, P., Aptsiauri, N., Ruiz-Cabello, F., & Garrido, F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00634-7 · Cited by 107 · see citing works
Self-citationThe Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy
Paucek, R. D., Baltimore, D., & Li, G. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.002 · Cited by 104 · see citing works
Epigenetic state determines the in vivo efficacy of STING agonist therapy
Falahat, R., Berglund, A., Perez-Villarroel, P., Putney, R. M., Hamaidi, I., Kim, S., Pilon-Thomas, S., Barber, G. N., & Mulé, J. J. (2023) · Nature Communications · doi:10.1038/s41467-023-37217-1 · Cited by 94 · see citing works
SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms
Wang, Y., Mohseni, M., Grauel, A., Diez, J. E., Guan, W., Liang, S., Choi, J. E., Pu, M., Chen, D., Laszewski, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-80999-x · Cited by 73 · see citing works
Phosphoinositide 3-kinase signaling can modulate MHC class I and II expression
Chandrasekaran, S., Sasaki, M., Scharer, C. D., Kissick, H. T., Patterson, D. G., Magliocca, K. R., Seykora, J. T., Sapkota, B., Gutman, D. A., Cooper, L. A., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0545 · Cited by 61 · see citing works
Bissonnette, R. P., Cesario, R. M., Goodenow, B., Shojaei, F., & Gillings, M. (2021) · BMC Cancer · doi:10.1186/s12885-021-08702-x · Cited by 24 · see citing works
Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer
Saillard, M., Cenerenti, M., Romero, P., & Jandus, C. (2021) · Vaccines · doi:10.3390/vaccines9050454 · Cited by 23 · see citing works
- Authors
- Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M., & van Hall, T.
- Affiliations
- Universidad de Granada (ES)
- Instituto de Investigación Biosanitaria de Granada (ES)
- Leiden University Medical Center (NL)
- Corresponding author
- Garrido, Federico
- Venue
- Current Opinion in Immunology
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 39
- Pages
- 44-51
- ISSN
- 0952-7915 (ISSN-L)
- PMC
- PMC5138279
- OpenAlex
- W2285621780
- Cited by
- 585
- References
- 73
- Citations by year
- 2026: 45 · 2025: 39 · 2024: 36 · 2023: 52 · 2022: 66 · 2021: 89 · 2020: 88 · 2019: 68 · 2018: 54 · 2017: 32 · 2016: 15
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Current Opinion in Immunology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Institutional Repository of the University of Granada (University of Granada) (publishedVersion, cc-by-nc-nd)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by-nc-nd)
- Funders
- FEDER (CP03/0111, PI12/02031, PI 08/1265, PI 11/01022, PI11/01386, PI14/01978, PI15/00528, RETIC RD 06/020, RD09/0076/00165, PT13/0010/0039)
- Junta de Andalucía in Spain (CTS-143, CTS-695, CTS-3952, CVI-4740, PI 09/0382)
- Worldwide Cancer Research (15-1166)
- Dutch Cancer Society (UL 2010-4785, TvH)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- MHC class I expression, tumor immune evasion, cancer immunotherapy, tumor rejection, tumor dormancy, tumor microenvironment, antigen presentation, immune checkpoint blockade
- MeSH terms
- Animals, Humans, Immunotherapy, Neoplasms, Histocompatibility Antigens Class I
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
